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cute promyelocytic leukemia 
(APL) was ﬁ  rst identiﬁ  ed as 
a distinct subtype of acute 
myeloid leukemia in 1957 by Leif 
Hillestad. It is called M3 in the 
French–American–British classiﬁ  cation, 
with a variant type referred to as 
microgranular (M3v in the French–
American–British nomenclature) [1]. 
APL is characterized by three features: 
(1) the presence of an accumulation 
of abnormal promyelocytes (see 
Glossary) that do not differentiate 
into mature granulocytes, (2) the 
occurrence of ﬁ  brinogenopenia 
and disseminated intravascular 
coagulation that is often worsened by 
chemotherapy, and (3) the presence of 
the speciﬁ  c chromosomal translocation 
t(15;17)(q22;q21) (Figure 1). 
APL accounts for 10%–15% of all 
cases of acute myeloid leukemia, with 
several thousand new cases diagnosed 
worldwide each year. Before the 
advent of differentiation therapy, 
APL was treated with anthracycline-
based chemotherapy with a complete 
remission rate of 60%–76% and a 
5-year event-free survival rate of 23%–
35% [1,2].
Differentiation Therapy: From 
Hypothesis to Practice 
Failure to differentiate terminally 
characterizes most, if not all, cancer 
cells of every origin. Whether the 
induction of differentiation could be a 
treatment strategy for cancers was hotly 
debated for decades before the advent 
of differentiation therapy. 
An important discovery of the early 
1970s was that myeloid leukemic cells 
could be reprogrammed to resume 
normal differentiation and to become 
non-dividing mature granulocytes or 
macrophages as a result of stimulation 
by various cytokines [3,4]. Based on this 
discovery, Leo Sachs at the Weizmann 
Institute of Science, Rehovot, Israel, 
hypothesized in 1978 that treatment 
with agents that induce cancer cells 
to complete differentiation could be 
a potential therapeutic option for 
patients with cancer [5]. In the early 
1980s, Breitman and colleagues showed 
that retinoic acid (RA; Figure 2), a 
derivative of vitamin A, could induce 
terminal differentiation of human 
promyelocytic leukemic cells in vitro 
[6,7]. But the ﬁ  rst clinical reports of 
using RA showed conﬂ  icting results. 
Some case reports showed beneﬁ  cial 
effects of 13-cis RA in people with 
refractory or relapsed APL [8,9,10], but 
other reports showed that 13-cis RA was 
ineffective in treating APL [11].
Beginning in the early 1980s, the 
Shanghai Institute of Hematology 
conducted a series of experiments on 
differentiation therapy for APL. These 
experiments showed that all-trans 
RA (ATRA) could induce terminal 
differentiation of HL-60, a cell line 
with promyelocytic features, and fresh 
leukemic cells from patients with 
APL. These intriguing results were the 
impetus for a clinical trial. Twenty-
four patients with APL were treated 
with ATRA (45 to 100 mg/m2/day). 
The result was dramatic: 23 patients 
(95.8%) went into complete remission 
(CR) without developing bone marrow 
hypoplasia or abnormalities of clotting. 
The remaining one patient achieved 
CR when chemotherapy was added 
[12]. Morphological maturation of 
bone marrow cells was found in all 
patients studied. 
These results were later conﬁ  rmed 
by many randomized studies in centers 
around the world. Further trials showed 
improved rates of CR, a decrease in 
severe adverse effects, and lengthening 
of the duration of remission. Table 1 
summarizes the CR rates obtained in 
most large series of patients. Currently, 
ATRA combined with anthracycline-
based chemotherapy can achieve CR 
in 90%–95% of patients with APL and 
overall 5-year disease-free survival in up 
to 75% of patients [13].
Arsenic: “Ancient Remedy Performs 
New Tricks”
Arsenic is a common, naturally 
occurring substance that exists in 
organic and inorganic forms in 
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nature. The organic arsenicals consist 
of an arsenic atom in its trivalent or 
pentavalent state linked covalently to a 
carbon atom. There are three inorganic 
forms of arsenic: red arsenic (As4S4, 
also known as “realgar”), yellow arsenic 
(As2S3, also known as “orpiment”), 
and white arsenic, or arsenic trioxide 
(As2O3) [14]. 
Arsenic was used to treat chronic 
myelogenous leukemia in the 18th and 
19th centuries, but was discarded as 
a treatment in the early 20th century 
because of its toxicity and the advent of 
radiation and cytotoxic chemotherapy. 
In the early 1970s, a group from 
Harbin Medical University in China 
found that intravenous infusions of 
Ailing-1, a crude solution composed 
of 1% arsenic trioxide with a trace 
amount of mercury chloride, induced 
CR in two-thirds of patients with APL. 
There was an impressive 30% survival 
rate after 10 years [15,16]. Pure arsenic 
trioxide at 0.16 mg/kg/day for 28–54 
days was shown to induce CR in 14 out 
of 15 (93.3%) patients with relapsed 
APL [17]. Tetra-arsenic tetra-sulﬁ  de 
was also reported to be effective in APL 
treatment [18]. 
Since 1996, a large number of 
reports have shown that arsenic 
compounds induce a CR in 85% 
to 90% of patients with both newly 
diagnosed and relapsed APL [13]. 
Furthermore, after CR is achieved 
by arsenic compounds, a molecular 
remission (i.e., negative for 
promyelocytic leukemia RA receptor 
α [PML-RARα] transcript detected 
by reverse transcriptase polymerase 
chain reaction) is obtainable either 
with arsenic compounds or with ATRA 
and chemotherapy as consolidation 
treatment. It seems likely that arsenic 
compounds appropriately used in 
post-remission therapy could prevent 
recurrence and achieve a longer 
survival time [13,18].
Studies have shown that arsenic 
trioxide exerts dose-dependent dual 
effects on APL cells—it induces 
apoptosis (programmed cell death) 
preferentially at relatively high 
concentrations (0.5 × 10−6 to 2 × 10−6 
M) and induces partial differentiation 
at low concentrations (0.1 × 10−6 to 
0.5 × 10−6 M). The rapid modulation 
and degradation of the PML-RARα 
oncoprotein by arsenic trioxide could 
contribute to these two effects [19].
How Do ATRA and Arsenic Work at 
the Molecular Level?
To understand how ATRA and arsenic 
compounds act at the molecular level 
in treating APL, it is ﬁ  rst important to 
understand the role of the PML-RARα 
fusion protein in the pathogenesis of 
APL.
Retinoids that are crucial for 
normal myeloid differentiation act 
via RA receptors (RARs) and retinoid 
X receptors (RXRs). These belong 
to the steroid/thyroid/retinoid 
nuclear receptor superfamily of 
ligand-inducible transcription factors. 
Both RAR and RXR families consist 
of three subtypes: α, β, and γ [20]. 
RARα forms a heterodimer with RXR 
and binds to RA response element 
to control the expression of target 
genes in the presence of physiological 
concentrations (10−9–10−8 M) of 
retinoids (Figure 3A). 
More than 95% of patients with 
APL have the t(15;17)(q22;q21) 
translocation. This results in the fusion 
of the RARα gene on 17q21 and the 
promyelocytic leukemia (PML) gene 
on 15q22, which generates a PML-
RARα fusion transcript [21,22]. Variant 
translocations can also be detected 
in APL. The PML-RARα chimeric 
protein acts as a dominant negative 
mutant over wild-type RARα. The 
chimeric protein prevents activation of 
key target genes required for normal 
myeloid differentiation by sequestering 
RXR and other RARα cofactors and 
inhibiting normal RARα functions. 
The PML-RARα oncoprotein binds to 
RAR target genes either on its own or 
with RXR and then recruits histone 
deacetlyase complexes, which act as 
repressors of transcription. 
PML-RARα may affect transcription 
in other pathways including those in 
which the transcription factor AP1 
and interferon-responsive factors are 
involved. PML-RARα also binds to 
promyelocytic leukemia zinc ﬁ  nger 
(PLZF) protein and potentially affects 
its functions (e.g., growth suppression 
and transcription repression; control 
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Figure 1. The Three Features of APL
The three features of APL are (A) accumulation of abnormal promyelocytes, (B) 
ﬁ  brinogenopenia and disseminated intravascular coagulation, and (C) the chromosomal 
translocation t(15;17)(q22;q21), the resultant fusion transcripts, and variants.
DOI: 10.1371/journal.pmed.0020012.g002
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of developmental programs and 
differentiation) [20]. In addition, 
PML-RARα prevents apoptosis 
through delocalization of PML and 
other proteins from the nuclear body. 
Finally, PML-RARα may cooperate 
with activated mutations in protein 
tyrosine kinases, such as FLT3 [23], 
which confer proliferative and/or 
survival advantage to hematopoietic 
stem/progenitor cells. Whether PML-
RARα affects the protein tyrosine 
kinase activity directly or indirectly 
is unclear. All these interactions of 
PML-RARα could be involved in the 
leukemogenesis of APL (Figure 3B). 
ATRA and arsenic trioxide 
degrade and cleave the PML-RARα 
oncoprotein. Although we now have a 
good understanding of the molecular 
mechanisms underlying ATRA in 
differentiation therapy for APL, these 
mechanisms were shown long after 
the identiﬁ  cation of the efﬁ  cacy of this 
drug in treating the disease. Now it is 
well established that pharmacological 
concentrations of ATRA (10−7–10−6 M) 
exert their effects through targeting 
the PML-RARα oncoprotein, triggering 
both a change in conﬁ  guration and 
degradation of the oncoprotein and 
the activation of transcription, leading 
to differentiation. Cleavage of the PML-
RARα fusion protein by caspases at 
residue D522 has been shown in APL 
cells induced to differentiate by ATRA 
[24]. 
Further dissecting of the pathways 
involved in PML-RARα catabolism 
led to the discovery of ubiquitin/
proteasome-mediated degradation 
of PML-RARα and RARα, which was 
dependent on the binding of SUG-1 
in the AF2 transactivation domain of 
RARα with 19S proteasome [25,26]. 
In contrast to ATRA, which targets 
the RARα moiety of the fusion, 
arsenic targets the PML moiety of 
PML-RARα, through a still unclear 
mechanism, and causes PML to 
localize to the nuclear matrix and 
become sumoylated. Sumoylation at 
K160 is necessary for 11S proteasome 
recruitment and arsenic-trioxide-
induced degradation, whereas 
sumoylation at K490 is needed for 
nuclear localization [27,28]. These 
results provide a striking similarity 
in the effect of these two otherwise 
unrelated agents (Figure 3C). 
The ﬁ  nal result of treatment 
with ATRA and arsenic trioxide 
is the degradation of the PML-
RARα oncoprotein, which results 
in restoration of normal retinoid 
signaling. RXR and PML sequestration 
is abrogated, and PML nuclear 
body is restored. The corepressor 
is released and the coactivator is 
recruited and bound with RARα; 
thus, the transcription of target 
genes is derepressed. ATRA also 
induces cyclic AMP, a differentiation 
enhancer that boosts transcriptional 
activation, reverses the silencing of the 
transactivating function of RXR, and 
restores ATRA-triggered differentiation 
in mutant ATRA-resistant APL cells 
[29]. Additionally, ATRA induces the 
expression of RA-induced genes [30] 
and cyclooxygenase 1 [31], inhibits 
angiogenesis [32], downregulates the 
expression of tissue factor [33], and 
restores other signal pathways (e.g., the 
interferon pathway). Consequently, the 
abnormal promyelocytes differentiate 
and die through programmed cell 
death (Figure 3C).
Combining ATRA and Arsenic: 
A Cure for APL?
Since ATRA and arsenic trioxide 
degrade the PML-RARα oncoprotein 
via different pathways, and since studies 
in animal models have shown synergic 
effects of both drugs in prolonging 
survival or even eliminating the disease 
[34,35], the group at the Shanghai 
Institute of Hematology hypothesized 
that the combination of the two drugs 
might synergize in treating APL. To 
test this, 61 patients newly diagnosed 
with APL were randomized into three 
treatment groups: ATRA, arsenic 
trioxide, or a combination of the two 
drugs [36]. Although CR rates in 
all three groups were high (>90%), 
the time to achieve CR differed 
signiﬁ  cantly—the time was shortest in 
patients treated with the combination. 
The disease burden (as reﬂ  ected by 
fold change of PML-RARα transcripts 
at CR) decreased signiﬁ  cantly more 
with combined therapy than with 
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Table 1. CR Rate in Patients with APL Treated with ATRA (in Series Including More Than 
50 Cases)
Year Researchers Protocol Sample Size CR (Percent) Reference
1991 Chen et al. ATRA 50 94.0 13
1992 Chinese Coop 
Study Group
ATRA
ATRA + chemo
400
144
85.0
76.4
13
1993 Shanghai Coop 
Study Group
ATRA 91 81.3 13
1994 Warrell et al. ATRA 79 84.8 13
1995 Kanamaru et al. ATRA ± chemo 109 89.0 13
1997 Tallman et al. ATRA 172 72.1 13
1997 Soignet et al. ATRA ± chemo 95 83.2 13
1997 Asou et al. ATRA
ATRA ± chemo
62
196
95.2
88.3
13
1997 Mandelli et al. ATRA ± chemo 240 95.4 13
1999 Burnett et al. ATRA (short) + chemo
ATRA (extended) + chemo
119
120
70.0
87.0
13
1999 Hu et al. ATRA + chemo 120 88.4 13
2000 Lengfelder et al. ATRA + high-dose cytosine 
arabinoside
51 92.0 13
2001 Asou et al. ATRA ± chemo
ATRA
ATRA + initial chemo
ATRA + later chemo
ATRA + initial, later chemo
369 90.0
94.0
89.0
88.0
86.0
13
2003 Bourgeois et al. ATRA± chemo 576 92.5 37–42
2003 Iland et al. ATRA± chemo 101 90 37–42
2003 Testi et al. ATRA± chemo 110 (<18 years) 96 37–42
2003 Avvisati et al. ATRA± chemo 807 94.3 37–42
2003 Ortega et al. ATRA± chemo 64 91 37–42
2003 Ades et al. ATRA± chemo 576
129 (>60 years)
447 (<60 yrs)
86
94
37–42
2003 Mandelli et al. ATRA± chemo 134 (>60 years)  86 43
Chemo, chemotherapy.
DOI: 10.1371/journal.pmed.0020012.t001PLoS Medicine  |  www.plosmedicine.org 0036
ATRA or arsenic trioxide monotherapy 
(p < 0.01), and this difference persisted 
after consolidation therapy (p < 
0.05). Notably, all 20 patients in the 
combination group remained in CR 
whereas seven of 37 cases treated with 
monotherapy relapsed (p < 0.05) after a 
follow-up of 8–30 months (median, 18 
months). 
It seems that a combination of ATRA 
and arsenic trioxide for remission 
and maintenance treatment of APL 
produces better results than either of 
the two drugs used alone, in terms of 
the time required to achieve CR and the 
length of disease-free survival. We hope 
that the use of three treatments—ATRA, 
arsenic trioxide, and chemotherapy—
will ultimately make APL a curable 
human acute myeloid leukemia [36].
Conclusion
The story of ATRA in the treatment 
of APL shows that by targeting the 
molecules critical to the pathogenesis 
of certain diseases, cells can be induced 
to return to normal. Differentiation 
therapy is therefore a practical method 
of treating human cancer that has 
shown consistent effectiveness in trials. 
The clariﬁ  cation of the underlying 
molecular abnormalities of APL is 
an example of the beneﬁ  ts of a close 
collaboration between bench and 
bedside, and is necessary for our 
understanding of the mechanisms 
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Figure 3. Leukemogenic Effects of PML-RARá 
and Mechanisms of ATRA/Arsenic Trioxide in 
the Treatment of APL
(A) In the absence of RA, RARα/RXR 
heterodimers recruit the transcription 
corepressor (CoR), which mediates 
transcriptional silencing by mechanisms 
that include direct inhibition of the basal 
transcription machinery and recruitment 
of chromatin-modifying enzymes. 
Chromatin modiﬁ  cation includes histone 
deacetylation, which leads to a compact 
chromatin structure that impairs the 
access of transcriptional activators. In the 
presence of physiological concentrations 
(10−9–10−8 M) of RA, the transcription 
corepressor is released and the 
coactivator is recruited to the RARα/
RXR heterodimer, resulting in histone 
acetylation (AC) and overcoming of the 
transcription blockage. 
(B) PML-RARα fusion protein binds to 
RARα target genes either on its own or 
with RXR and then recruits corepressors, 
leading to transcriptional repression 
and myeloid differentiation inhibition. 
PML-RARα oncoprotein sequesters 
the normal RXR and PML, inhibits 
the PML/P53 apoptotic pathway, and 
delocalizes PML and other proteins 
from the nuclear body. PML-RARα also 
may affect interferon (IFN) and other 
signal pathways. Abnormalities in protein 
tyrosine kinases (e.g., FLT3, c-fms) may 
collaborate with PML-RARα to cause 
APL. 
(C) In the presence of pharmacological 
doses of ATRA or arsenic trioxide, 
the PML-RARα fusion is degraded in 
ways that are dependent on caspases 
and proteasomes. The degradation of 
PML-RARα may lead to derepression of 
transcription suppression and restoration 
of PML nuclear body structure. The 
blockade of other signaling pathways 
is also released, and the anti-apoptotic 
effect of PML-RARα is lost. ATRA also 
induces cyclic AMP (cAMP), which 
reverses the silencing of RXR, induces 
the expression of RA-induced genes 
and cyclooxygenase 1 (Cox 1), inhibits 
angiogenesis, and downregulates tissue 
factor. Subsequently, ATRA induces 
terminal cell differentiation, while arsenic trioxide induces partial differentiation and/or apoptosis of APL cells. The effects of ATRA 
and arsenic trioxide are indicated with red and blue arrows, respectively. 
AF2, the ligand-dependent transcriptional activation domain contained within the C-terminal E domain of RARα; D522, aspartate at 
residue 522; K160, lysine at residue 160; K490, lysine at residue 490; RARE, retinoic acid response element; SUG-1, a component of 
proteasome 19S complex that can bind with the activated AF2 domain of RARα. PLoS Medicine  |  www.plosmedicine.org 0037
of ATRA in differentiation therapy. 
It is clearly important to elucidate 
the molecular and cellular basis of a 
particular cancer if we are to further 
develop mechanism-based target 
therapies. 
The sequencing of the human 
genome and ongoing functional 
genomic research are now accelerating 
the dissection of disease mechanisms 
and identiﬁ  cation of therapeutic 
targets. This in turn may facilitate the 
screening of promising treatments. 
What we learn from developing 
curative treatment approaches to APL 
may help to conquer other types of 
leukemias and cancers.  
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Glossary
Apoptosis: A genetically determined 
process of cell death in which the cell 
uses specialized cellular machinery 
to kill itself and is then eliminated by 
phagocytosis or by shedding.
Caspase: A family of cysteine proteases 
with aspartate speciﬁ  city that are 
essential intracellular death effectors.
Disseminated intravascular 
coagulation: A hemorrhagic disorder 
that occurs following the uncontrolled 
activation of clotting factors and 
ﬁ  brinolytic enzymes throughout small 
blood vessels, resulting in depletion of 
clotting factors and tissue necrosis and 
bleeding.
Fibrinogenopenia: A decrease in 
concentration of ﬁ  brinogen in the blood.
Granulocyte: Terminally differentiated 
myelocyte or polymorphonuclear white 
blood cell (as a basophil, eosinophil, or 
neutrophil) with granule-containing 
cytoplasm.
Ligand-inducible transcription 
factors: Transcription factors that 
structurally have domains associated 
with DNA binding and ligand (hormone) 
recognition. When binding to its speciﬁ  c 
ligand, the transcription factor initiates 
a series of conformational changes and 
interacts efﬁ  ciently with its speciﬁ  c DNA 
response element to recruit components 
of the transcriptional machinery. 
Nuclear receptor superfamily: 
One of the most abundant classes of 
transcriptional regulators including 
receptors for steroid hormones (e.g., 
estrogens, glucocorticoids, and vitamin 
D3), RAs, thyroid hormones, and so on. 
These transcription factors regulate 
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